nach oben

Erschienen in:

01.03.2010 | Original Article

SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo

verfasst von: Jennifer P. Arbitrario, Brian J. Belmont, Marc J. Evanchik, W. Michael Flanagan, Raymond V. Fucini, Stig K. Hansen, Shannon O. Harris, Ahmad Hashash, Ute Hoch, Jennifer N. Hogan, Anthony R. Howlett, Jeffrey W. Jacobs, Joni W. Lam, Sean C. Ritchie, Michael J. Romanowski, Jeffrey A. Silverman, David E. Stockett, Juli N. Teague, Kristin M. Zimmerman, Pietro Taverna

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The Aurora family of serine/threonine kinases (Aurora-A, Aurora-B, and Aurora-C) plays a key role in cells orderly progression through mitosis. Elevated expression levels of Aurora kinases have been detected in a high percentage of melanoma, colon, breast, ovarian, gastric, and pancreatic tumors. We characterized the biological and pharmacological properties of SNS-314, an ATP-competitive, selective, and potent inhibitor of Aurora kinases.

Methods

We studied the biochemical potency and selectivity of SNS-314 to inhibit Aurora kinases A, B, and C. The inhibition of cellular proliferation induced by SNS-314 was evaluated in a broad range of tumor cell lines and correlated to inhibition of histone H3 phosphorylation, inhibition of cell-cycle progression, increase in nuclear content and cell size, loss of viability, and induction of apoptosis. The dose and administration schedule of SNS-314 was optimized for in vivo efficacy in mouse xenograft models of human cancer.

Results

In the HCT116 human colon cancer xenograft model, administration of 50 and 100 mg/kg SNS-314 led to dose-dependent inhibition of histone H3 phosphorylation for at least 10 h, indicating effective Aurora-B inhibition in vivo. HCT116 tumors from animals treated with SNS-314 showed potent and sustained responses including reduction of phosphorylated histone H3 levels, increased caspase-3 and appearance of increased nuclear size. The compound showed significant tumor growth inhibition in a dose-dependent manner under a variety of dosing schedules including weekly, bi-weekly, and 5 days on/9 days off.

Conclusions

SNS-314 is a potent small-molecule inhibitor of Aurora kinases developed as a novel anti-cancer therapeutic agent for the treatment of diverse human malignancies.

Nur mit Berechtigung zugänglich

Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN Jr, Gandara DR (2008) Aurora kinases as anticancer drug targets. Clin Cancer Res 14:1639–1648CrossRefPubMed

Carmena M, Earnshaw WC (2003) The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 4:842–854CrossRefPubMed

Katayama H, Brinkley WR, Sen S (2003) The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev 22:451–464CrossRefPubMed

Naruganahalli KS, Lakshmanan M, Dastidar SG, Ray A (2006) Therapeutic potential of Aurora kinase inhibitors in cancer. Curr Opin Investig Drugs 7:1044–1051PubMed

Kimura M, Matsuda Y, Yoshioka T, Okano Y (1999) Cell cycle-dependent expression and centrosome localization of a third human aurora/Ipl1-related protein kinase, AIK3. J Biol Chem 274:7334–7340CrossRefPubMed

Li X, Sakashita G, Matsuzaki H et al (2004) Direct association with inner centromere protein (INCENP) activates the novel chromosomal passenger protein, Aurora-C. J Biol Chem 279:47201–47211CrossRefPubMed

Sasai K, Katayama H, Stenoien DL et al (2004) Aurora-C kinase is a novel chromosomal passenger protein that can complement Aurora-B kinase function in mitotic cells. Cell Motil Cytoskelet 59:249–263CrossRef

Sen S, Zhou H, White RA (1997) A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines. Oncogene 14:2195–2200CrossRefPubMed

Jeng YM, Peng SY, Lin CY, Hsu HC (2004) Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin Cancer Res 10:2065–2071CrossRefPubMed

10.

Hu W, Kavanagh JJ, Deaver M et al (2005) Frequent overexpression of STK15/Aurora-A/BTAK and chromosomal instability in tumorigenic cell cultures derived from human ovarian cancer. Oncol Res 15:49–57PubMed

11.

Tanaka E, Hashimoto Y, Ito T et al (2005) The clinical significance of Aurora-A/STK15/BTAK expression in human esophageal squamous cell carcinoma. Clin Cancer Res 11:1827–1834CrossRefPubMed

12.

Tchatchou S, Wirtenberger M, Hemminki K et al (2007) Aurora kinases A and B and familial breast cancer risk. Cancer Lett 247:266–272CrossRefPubMed

13.

Vischioni B, Oudejans JJ, Vos W, Rodriguez JA, Giaccone G (2006) Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients. Mol Cancer Ther 5:2905–2913CrossRefPubMed

14.

Katayama H, Ota T, Jisaki F et al (1999) Mitotic kinase expression and colorectal cancer progression. J Natl Cancer Inst 91:1160–1162CrossRefPubMed

15.

Bischoff JR, Anderson L, Zhu Y et al (1998) A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J 17:3052–3065CrossRefPubMed

16.

Tarnawski A, Pai R, Chiou SK, Chai J, Chu EC (2005) Rebamipide inhibits gastric cancer growth by targeting survivin and Aurora-B. Biochem Biophys Res Commun 334:207–212CrossRefPubMed

17.

Lee EC, Frolov A, Li R, Ayala G, Greenberg NM (2006) Targeting Aurora kinases for the treatment of prostate cancer. Cancer Res 66:4996–5002CrossRefPubMed

18.

Chieffi P, Cozzolino L, Kisslinger A et al (2006) Aurora B expression directly correlates with prostate cancer malignancy and influence prostate cell proliferation. Prostate 66:326–333CrossRefPubMed

19.

Wilkinson RW, Odedra R, Heaton SP et al (2007) AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res 13:3682–3688CrossRefPubMed

20.

Harrington EA, Bebbington D, Moore J et al (2004) VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 10:262–267CrossRefPubMed

21.

Carpinelli P, Ceruti R, Giorgini ML et al (2007) PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer. Mol Cancer Ther 6:3158–3168CrossRefPubMed

22.

Manfredi MG, Ecsedy JA, Meetze KA et al (2007) Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc Natl Acad Sci USA 104:4106–4111CrossRefPubMed

23.

Oslob JD, Romanowski MJ, Allen DA et al (2008) Discovery of a potent and selective Aurora kinase inhibitor. Bioorg Med Chem Lett 18:4880–4884CrossRefPubMed

24.

Zhang Y-X, Knyazev PG, Cheburkin YV et al (2008) AXL is a potential target for therapeutic intervention in breast cancer progression. Cancer Res 68:1905–1915CrossRefPubMed

25.

Sridhar SS, Hedley D, Siu LL (2005) Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther 4:677–685CrossRefPubMed

26.

Vogel W (1999) Discoidin domain receptors: structural relations and functional implications. FASEB J 13:77–82

27.

Karkkainen MJ, Petrova TV (2000) Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene 19:5598–5605CrossRefPubMed

28.

Roussel MF, Sherr CJ (2003) Oncogenic potential of the c-FMS proto-oncogene (CSF-1 receptor). Cell Cycle 2:5–6PubMed

29.

Pierotti MA, Greco A (2006) Oncogenic rearrangements of the NTRK1/NGF receptor. Cancer Lett 232:90–98CrossRefPubMed

30.

Festuccia C, Gravina GL, Millimaggi D et al (2007) Uncoupling of the epidermal growth factor receptor from downstream signal transduction molecules guides the acquired resistance to gefitinib in prostate cancer cells. Oncol Rep 18:503–511PubMed

31.

Chan F, Sun C, Perumal M et al (2007) Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity. Mol Cancer Ther 6:3147–3157CrossRefPubMed

32.

Soncini C, Carpinelli P, Gianellini L et al (2006) PHA-680632, a novel Aurora kinase inhibitor with potent antitumoral activity. Clin Cancer Res 12:4080–4089CrossRefPubMed

33.

Monier K, Mouradian S, Sullivan KF (2007) DNA methylation promotes Aurora-B-driven phosphorylation of histone H3 in chromosomal subdomains. J Cell Sci 120:101–114CrossRefPubMed

34.

Evanchik M, Hogan J, Arbitrario J, et al (2008) SNS-314, a potent inhibitor of Aurora kinases, has preclinical anti-tumor activity and induces apoptosis. AACR Meeting Abstracts 2008, p. 5648

35.

Carpinelli P, Moll J (2008) Aurora kinase inhibitors: identification and preclinical validation of their biomarkers. Expert Opin Ther Targets 12:69–80CrossRefPubMed

36.

Elling RA, Tangonan BT, Penny DM et al (2007) Mouse Aurora A: expression in Escherichia coli and purification. Protein Expr Purif 54:139–146CrossRefPubMed

37.

Ellis RJ, van der Vies SM (1991) Molecular chaperones. Annu Rev Biochem 60:321–347CrossRefPubMed

38.

Thain A, Gaston K, Jenkins O, Clarke AR (1996) A method for the separation of GST fusion proteins from co-purifying GroEL. Trends Genet 12:209–210CrossRefPubMed

39.

Hansen SK, Cancilla MT, Shiau TP, Kung J, Chen T, Erlanson DA (2005) Allosteric inhibition of PTP1B activity by selective modification of a non-active site cysteine residue. Biochemistry 44:7704–7712CrossRefPubMed

Titel: SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo
verfasst von: Jennifer P. Arbitrario
Brian J. Belmont
Marc J. Evanchik
W. Michael Flanagan
Raymond V. Fucini
Stig K. Hansen
Shannon O. Harris
Ahmad Hashash
Ute Hoch
Jennifer N. Hogan
Anthony R. Howlett
Jeffrey W. Jacobs
Joni W. Lam
Sean C. Ritchie
Michael J. Romanowski
Jeffrey A. Silverman
David E. Stockett
Juli N. Teague
Kristin M. Zimmerman
Pietro Taverna
Publikationsdatum: 01.03.2010
Verlag: Springer-Verlag
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 4/2010
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-009-1076-8

Springer Medizin

SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo